ERBB2 and breast carcinoma: ,2 The first antibody-drug conjugate approved for breast cancer (BC) treatment, T-DM1 is composed of the HER2-targeted antibody, trastuzumab, stably linked to DM1, a cytotoxic microtubule-inhibiting drug.3